Erratum: Cost-Effectiveness of a Community Pharmacist Intervention in Patients with Depression: A Randomized Controlled Trial (PRODEFAR Study) (PLoS ONE (2013) 8:8 (e70588) 10.1371/journal.pone.0070588);Cost-Effectiveness of a Community Pharmacist Intervention in Patients with Depression: A Randomized Controlled Trial (PRODEFAR Study)

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Rubio Valera, Maria ^a,b   Bosmans, Judith ^c   Fernández, Ana ^a,b,d   Peñarrubia María, Maite ^b,e   March, Marian ^f   Travé, Pere ^f   Bellón, Juan A ^b,g   Serrano Blanco, Antoni ^a,b  

^a Research and Development Unit   (Spain)

^b redIAPP (Red de Investigacion en Actividades Preventivas y Promocion de la Salud en Atencion Primari   (Spain)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e INSTITUT CATALÀ DE LA SALUT   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; COMMUNITY CARE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST; PRIMARY MEDICAL CARE; PROBABILITY; PRODUCTIVITY; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYMPTOM;

ADULT; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INTERVENTION STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACIES; PHARMACISTS; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 84881492738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147459     Document Type: Erratum

References (41)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, et al. (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl: pp. 21-27.
2. Mathers CD, Loncar D, (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442 Available: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0030442.
3. Sturm R, Wells KB, (1995) How can care for depression become more cost-effective? JAMA 273: 51-58.
4. Sobocki P, Jonsson B, Angst J, Rehnberg C, (2006) Cost of depression in Europe. J Ment Health Policy Econ 9: 87-98.
5. Commission of the European Communities (2005) Green Paper. Improving the mental health of the population. Towards a strategy on mental health for the European Union. Brussels.
6. Salvador-Carulla L, Bendeck M, Fernandez A, Alberti C, Sabes-Figuera R, et al. (2011) Costs of depression in Catalonia (Spain). J Affect Disord 132: 130-138.
7. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, et al. (2004) Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl: pp. 47-54.
8. Rubio-Valera M, Fernandez A, Luciano JV, Hughes CM, Pinto-Meza A, et al. (2012) Psychotropic prescribing in Catalonia: results from an epidemiological study. Fam Pract 29: 154-162.
9. Chen SY, Hansen RA, Gaynes BN, Farley JF, Morrissey JP, et al. (2010) Guideline-concordant antidepressant use among patients with major depressive disorder. Gen Hosp Psychiatry 32: 360-367.
10. Prukkanone B, Vos T, Burgess P, Chaiyakunapruk N, Bertram M, (2010) Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand. BMC Psychiatry 10: 64 Available: http://www.biomedcentral.com/1471-244X/10/64.
11. Serna MC, Cruz I, Real J, Gasco E, Galvan L, (2010) Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 25: 206-213.
12. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, et al. (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361: 653-661.
13. Simon GE, (2002) Evidence review: efficacy and effectiveness of antidepressant treatment in primary care. Gen Hosp Psychiatry 24: 213-224.
14. Demyttenaere K, Adelin A, Patrick M, Walthère D, Katrien de B, et al. (2008) Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol 23: 36-42.
15. Chong WW, Aslani P, Chen TF, (2011) Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. Int J Clin Pract 65: 954-975.
16. Rubio-Valera M, Serrano-Blanco A, Magdalena-Belio J, Fernandez A, Garcia-Campayo J, et al. (2011) Effectiveness of pharmacist care in the improvement of adherence to antidepressants: a systematic review and meta-analysis. Ann Pharmacother 45: 39-48.
17. Rubio-Valera M, March Pujol M, Fernández A, Peñarrubia-María MT, Travé P, et al. (2012) Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: A randomized controlled superiority trial. Eur Neuropsychopharmacol In press. Available: http://www.europeanneuropsychopharmacology.com/article/S0924-977X(12)00318-5/abstract.
18. Bosmans JE, Brook OH, Van Hout HP, de Bruijne MC, Nieuwenhuyse H, et al. (2007) Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants. Pharmacoeconomics 25: 25-37.
19. Glick HA, Doshi JA, Sonnad SS, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press.
20. Rubio-Valera M, Serrano-Blanco A, Trave P, Penarrubia-Maria MT, Ruiz M, et al. (2009) Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol. BMC Public Health 9: 284 Available: http://www.biomedcentral.com/1471-2458/9/284.
21. First MB, Spitzer RL, Gibbon M, William JB (1996) Structured Clinical Interview Axis I DSM-IV Disorders, Research Version (SCID-RV). Washington: American Psychiatric Press, Inc.
22. First MB, Spitzer RL, Gibbon M, William JB (1999) Entrevista clínica estructurada para los trastornos del eje I del DSM-IV. Barcelona, Spain: Masson ed.
23. Hansen RA, Kim MM, Song L, Tu W, Wu J, et al. (2009) Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 43: 413-422.
24. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, et al. (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10: 3-12.
25. The EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16: 199-208.
26. Badia X, Schiaffino A, Alonso J, Herdman M, (1998) Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 7: 311-322.
27. Badia X, Roset M, Montserrat S, Herdman M, Segura A, (1999) [The Spanish version of EuroQol: a description and its applications. European Quality of Life scale]. Med Clin (Barc) 112: 79-85.
28. Dolan P, Gudex C, Kind P, Williams A, (1995) A social tariff for EuroQol: Results from a UK general population survey. University of York: Centre for Health Economics. Discussion Paper 138.
29. Spitzer RL, Kroenke K, Williams JB, (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282: 1737-1744.
30. Kroenke K, Spitzer RL, Williams JB, (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16: 606-613.
31. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP, (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 72: 464-472.
32. Knapp M (PSSRU and Centre for Economics of Mental Health IoP, University of Kent) (1995) The Economic evaluation of Mental Health Care. Ashgate Publishing Group.
33. [Resolution SLT/383/2009 of 21 January 2009 of the Official Gazette of the Catalan Government (Diari Oficial de la Generalitat de Catalunya) DOGC Number 5325].
34. Official College of Medical Doctors of Barcelona. Available: http://www.comb.cat/home.aspx. Accessed 2012 February 15.
35. Spanish National Institute of Statistics. Available: www.ine.es. Accessed 2012 March 5.
36. ASPIME (2011) XII Edition of the Annual Report on Community Pharmacies.
37. White IR, Royston P, Wood AM, (2011) Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30: 377-399.
38. Rubin D (1987) Multiple imputation for nonresponse in surveys. New York: Wiley.
39. Efron B, (1994) Missing data, imputation, and the bootstrap. J Am Stat Assoc 89: 463-475.
40. Fenwick E, Byford S, (2005) A guide to cost-effectiveness acceptability curves. Br J Psychiatry 187: 106-108.
41. Schoenbaum M, Unutzer J, Sherbourne C, Duan N, Rubenstein LV, et al. (2001) Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA 286: 1325-1330.